Anagrelide Capsules — Class II drug recall D-1862-2019
Terminated recall by Torrent Pharma Inc., reported 2019-09-25, distributed nationwide. Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during
| Recall number | D-1862-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Torrent Pharma Inc., Basking Ridge, NJ, United States |
| Recall initiated | 2019-09-06 |
| Classified | 2019-09-16 |
| Reported by FDA | 2019-09-25 |
| Terminated | 2020-11-03 |
| Distributed | Nationwide (US) |
| Quantity | 2,472 bottles |
| Reason classes | specification failure |
| NDC | 13668-0453, 13668-0453-01, 13668-0453-30, 13668-0462, 13668-0462-01, 13668-0462-30 |
| Lot numbers | BFE2E003 |
| Expiration dates | 2020-08-31 |
Product
Anagrelide Capsules, USP, 0.5 mg, 100-count bottle, Rx only, Manufactured in India for: Torrent Pharma Inc., Basking Ridge, NJ 07920, NDC 13668-453-01.
Reason for recall
Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1862-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.